Publications for Lars Cöster
Co-author map based on ISI articles 2007-

Publications mentioned in social media 3 times*

Keywords

widespread treatment tnf tb risks risk rheumatoid register ra population patients pain necrosis lymphoma cohort cancer biologics arthritis anti-tnf antagonists

Journal Articles

Christopher Sjöwall and Lars Cöster
  Belimumab may not prevent lupus nephritis in serologically active patientswith ongoing non-renal disease activity
  Scandinavian Journal of Rheumatology, 2014, , .

Alf Kastbom, Lars Cöster, Lisbeth Ärlestig, Aikaterini Chatzidionysiou, Ronald F. van Vollenhoven, Leonid Padyukov, Solbritt Rantapää-Dahlqvist and Saedis Saevarsdottir
  Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study
  BMJ Open, 2012, 2(5), .
   Fulltext  PDF  
 Web of Science® Times Cited: 3

Julia F Simard, Elizabeth V Arkema, Tore Saxne, Eva Baecklund, Lars Cöster, Christina Dackhammar, Lennart Jacobsson, Nils Feltelius, Staffan Lindblad, Solbritt Rantapaa-Dahlqvist, Lars Klareskog, Ronald F van Vollenhoven and Martin Neovius
  Ten years with biologics: to whom do data on effectiveness and safety apply?
  RHEUMATOLOGY, 2011, 50(1), 204-213.
 Web of Science® Times Cited: 13

Johan Askling, Ronald F van Vollenhoven, Fredrik Granath, Pauline Raaschou, C Michael Fored, Eva Baecklund, Christina Dackhammar, Nils Feltelius, Lars Cöster, Pierre Geborek, Lennart T Jacobsson, Staffan Lindblad, Solbritt Rantapaa-Dahlqvist, Tore Saxne and Lars Klareskog
  Cancer Risk in Patients With Rheumatoid Arthritis Treated With Anti-Tumor Necrosis Factor alpha Therapies Does the Risk Change With the Time Since Start of Treatment?
 
Altmetric usage: 1

  ARTHRITIS AND RHEUMATISM, 2009, 60(11), 3180-3189.

R.F. van Vollenhoven, S. Ernestam, P. Geborek, I.F. Petersson, Lars Cöster, E. Waltbrand, A. Zickert, J. Theander, A. Thorner, H. Hellstrom, A. Teleman, C. Dackhammar, F. Akre, K. Forslind, L. Ljung, R. Oding, A. Chatzidionysiou, M. Wornert and J. Bratt
  Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
 
Altmetric usage: 1

  The Lancet, 2009, 374(9688), 459-466.
 Web of Science® Times Cited: 98

J Askling, E Baecklund, F Granath, P Geborek, M Fored, C Backlin, L Bertilsson, Lars Cöster, L T Jacobsson, S Lindblad, J Lysholm, S Rantapaa-Dahlqvist, T Saxne, R van Vollenhoven, L Klareskog and N Feltelius
  Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register
 
Altmetric usage: 1

  ANNALS OF THE RHEUMATIC DISEASES, 2009, 68(5), 648-653.

Lars Cöster, Sally Kendall, Björn Gerdle, Chris Henriksson, Karl-Gösta Henriksson and Ann Bengtsson
  Chronic widespread musculoskeletal pain - A comparison of those who meet criteria for fibromyalgia and those who do not
  European Journal of Pain, 2008, 12(5), 600-610.
 Web of Science® Times Cited: 40

Björn Gerdle, Jonas Björk, Lars Cöster, Karl-Gösta Henriksson, Chris Henriksson and Ann Bengtsson
  Prevalence of widespread pain and associations with work status: A population study
  BMC Musculoskeletal Disorders, 2008, 9, .
 Web of Science® Times Cited: 20

J Askling, CM Fored, L Brandt, E Baecklund, L Bertilsson, N Feltelius, Lars Cöster, P Geborek, LT Jacobsson, S Lindblad, J Lysholm, S Rantapää-Dahlqvist, T Saxne, RF van Vollenhoven and L Klareskog
  Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists
  Annals of the Rheumatic Diseases, 2007, 66(10), 1339-1344.
 Web of Science® Times Cited: 128

Johan Askling, Michael Fored, Lena Brandt, Eva Baecklund, Lennart Bertilsson, Lars Cöster, Pierre Geborek, Lennart T Jacobsson, Staffan Lindblad, Jörgen Lysholm, Solbritt Rantapää-Dahlqvist, Tore Saxne, Victoria Romanus, Lars Klareskog and Nils Feltelius
  Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden
  Arthritis and Rheumatism, 2005, 52(7), 1986-1992.
 Web of Science® Times Cited: 157

J Askling, CM Fored, E Baecklund, L Brandt, C Backlin, A Ekbom, C Sundström, L Bertilsson, Lars Cöster, P Geborek, Lt Jacobsson, S Lindblad, J Lysholm, S Rantapää-Dahlqvist, T Saxne, L Klareskog and N Feltelius
  Haematopoietic malignancies in rheumatoid arthritis: Lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists
  Annals of the Rheumatic Diseases, 2005, 64(10), 1414-1420.
 Web of Science® Times Cited: 196

J Askling, CM Fored, L Brandt, E Baecklund, L Bertilsson, N Feltelius, Lars Cöster, P Geborek, LT Jacobsson, S Lindblad, J Lysholm, S Rantapää-Dahlqvist, T Saxne and L Klareskog
  Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
  Annals of the Rheumatic Diseases, 2005, 64(10), 1421-1426.
 Web of Science® Times Cited: 166

Conference Articles

Carl Turesson, Lars Cöster and Jorgen Lysholm
  RHEUMATOID ARTHRITIS: INSIGHTS, STRATEGIES AND EXPECTATIONS?SWEDISH RESULTS OF THE RAISE PATIENT NEEDS SURVEY in SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, vol 39, issue , pp 23-23
  SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2010.


* Social media data based on publications from 2011 to present and with a DOI; data delivered by Altmetric.com.